Matt Labenski
About Matt Labenski
Matt Labenski serves as the Senior Director of Proteomics and Chemical Biology at Jnana Therapeutics, where he has worked since 2017. He has a background in pharmacology and toxicology, holding a Ph.D. from the University of Arizona and extensive experience in the pharmaceutical industry.
Current Role at Jnana Therapeutics
Matt Labenski serves as the Senior Director of Proteomics and Chemical Biology at Jnana Therapeutics. He has held this position since 2017, contributing to the company's mission of developing innovative therapies. His work focuses on integrating proteomics and chemical biology to advance drug discovery and development processes. Located in Boston, Massachusetts, Jnana Therapeutics aims to create novel treatment platforms for patients in need.
Previous Experience in the Pharmaceutical Industry
Before joining Jnana Therapeutics, Matt Labenski held several significant roles in the pharmaceutical sector. He worked as a Principal Scientist at Celgene from 2012 to 2017 in Bedford, MA. Prior to that, he was an Associate Scientist at Praecis Pharmaceuticals from 2001 to 2003, also in Waltham, MA. His career began as a Scientist at Avila Therapeutics, where he worked from 2008 to 2011. These positions provided him with extensive experience in drug development and scientific research.
Educational Background in Pharmacology and Toxicology
Matt Labenski earned his Doctor of Philosophy (Ph.D.) in Pharmacology and Toxicology from the University of Arizona, completing his studies from 2003 to 2008. His academic background also includes a Bachelor's degree in Toxicology from Northeastern University, which he obtained from 1997 to 2001. This educational foundation has equipped him with the knowledge and skills necessary for his roles in the pharmaceutical industry.
Inspiration and Professional Motivation
Matt Labenski is inspired by the challenges associated with developing novel therapeutic platforms for patients and their families. His commitment to improving the quality of life for individuals in need of effective treatments drives his work in proteomics and chemical biology. This motivation reflects a dedication to addressing unmet medical needs through innovative scientific approaches.